The Global Equine Chorionic Gonadotropin (eCG) for Injection Market was valued at USD 257 million in 2023 and is projected to reach USD 391.91 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.80% during the forecast period (2023-2032). This growth is being driven by increasing demand for livestock reproductive management, technological advancements in hormone extraction, and expanding veterinary healthcare infrastructure across emerging markets.
As the animal health industry seeks to optimize breeding efficiency and food production, eCG (also known as PMSG) serves as a critical tool for veterinary reproduction. In this analysis, we examine the Top 10 Companies in the Equine Chorionic Gonadotropin for Injection Market—a combination of established pharmaceutical leaders and specialized biologics manufacturers transforming reproductive health solutions.
🔟 1. MSD Animal Health
Headquarters: Madison, New Jersey, USA
Key Offering: Comprehensive eCG-based veterinary pharmaceuticals
As the animal health division of Merck & Co., MSD Animal Health dominates the global veterinary medicine market with reproductive hormone solutions. The company’s eCG products are utilized in 70+ countries through an extensive agricultural distribution network.
Innovation Edge:
- Pioneering research in reproductive hormone standardization
- Integrated livestock fertility management systems
- Strategic partnerships with commercial breeding operations
Download FREE Sample Report: Equine Chorionic Gonadotropin (eCG) for Injection Market – View in Detailed Research Report
9️⃣ 2. Ceva Santé Animale
Headquarters: Libourne, France
Key Offering: Advanced eCG formulations for estrus synchronization
This French veterinary pharmaceutical leader specializes in reproductive solutions, with eCG products accounting for 18% of their reproductive portfolio revenue. Their specialized formulations are particularly effective in swine and cattle breeding programs.
Key Differentiators:
- Proprietary purification technologies
- Veterinary technical support teams in 45 countries
- Growing market share in Latin American pork industries
8️⃣ 3. Syntex SA
Headquarters: Buenos Aires, Argentina
Key Offering: Pregnant Mare Serum Gonadotropin (PMSG/eCG)
Leveraging Argentina’s robust equine industry, Syntex SA has become a global leader in equine-derived reproductive hormones. The company sources from over 5,000 mares annually, maintaining strict welfare and collection standards.
Market Advantages:
- Vertical integration from breeding to final product
- Cost efficiencies in raw material sourcing
- 35% market share in South American livestock sectors
7️⃣ 4. Bioveta
Headquarters: Ivanovice na Hané, Czech Republic
Key Offering: EU-compliant eCG formulations
With 70+ years in veterinary biologics, Bioveta has perfected hormone extraction techniques that meet stringent European quality standards. Their products are indispensable for EU livestock producers facing strict regulatory requirements.
Technical Superiority:
- ISO 9001 and EU GMP certified facilities
- Precision formulation for consistent potency
- Leading supplier to Eastern European markets
Download FREE Sample Report: Equine Chorionic Gonadotropin (eCG) for Injection Market – View in Detailed Research Report
6️⃣ 5. Ningbo Sansheng Biological Technology
Headquarters: Ningbo, China
Key Offering: Cost-competitive eCG solutions
As China’s second-largest veterinary biologics producer, Ningbo Sansheng has captured 22% of the domestic eCG market. The company is expanding rapidly across Southeast Asia with government-supported agricultural initiatives.
Strategic Position:
- Annual production capacity of 15 million IU
- Strategic pricing for emerging markets
- Integrated cold chain distribution network
5️⃣ 6. Ningbo Second Hormone Factory
Headquarters: Ningbo, China
Key Offering: Specialized reproductive hormones
This Chinese manufacturer focuses exclusively on hormonal products, with eCG representing 65% of their production output. Their dedicated facilities allow for specialized quality control in hormone purification.
Production Capabilities:
- 5 specialized purification lines for eCG
- 80,000 square foot GMP facility
- Exports to 30+ developing markets
4️⃣ 7. Chifeng Bo-en Pharmaceutical
Headquarters: Inner Mongolia, China
Key Offering: Equine-sourced biological products
Located in China’s premier equine breeding region, Chifeng Bo-en combines traditional husbandry with modern extraction technologies. Their rural operations provide cost advantages while maintaining strict quality protocols.
Regional Strengths:
- Direct access to 3,000+ breeding mares
- Manufacturing costs 20% below industry average
- Strong government agricultural subsidies
3️⃣ 8. Guangzhou Vbio-Pharma
Headquarters: Guangzhou, China
Key Offering: Integrated reproductive health solutions
This biotechnology innovator combines eCG production with companion diagnostic tools, offering complete reproductive management systems. Their R&D focus targets precision breeding applications.
Technical Integration:
- Combination hormone-testing kits
- Smart breeding management software
- 15% annual R&D budget growth
2️⃣ 9. JALLY
Headquarters: Seoul, South Korea
Key Offering: Ultra-purified eCG formulations
JALLY’s advanced purification technologies set new standards for hormone product quality in Asia. Their products command premium pricing in markets where efficacy and safety are paramount concerns.
Quality Leadership:
- 99.5% purity benchmarks
- Strict batch-to-batch consistency
- Preferred supplier for Japanese/Korean markets
1️⃣ 10. Ningbo Creator Animal Pharmaceutical
Headquarters: Ningbo, China
Key Offering: Budget eCG solutions
This aggressive market entrant has gained share through competitive pricing and rapid production scaling. Their cost-focused approach makes eCG accessible to small-scale livestock operations across developing regions.
Growth Strategy:
- 30% annual capacity expansion
- Focus on price-sensitive African markets
- Strategic mare leasing programs
Read Full Report: Equine Chorionic Gonadotropin (eCG) for Injection Market – View in Detailed Research Report
🌍 Outlook: The Future of the eCG for Injection Market
The equine chorionic gonadotropin sector is entering a transformative phase, where biological innovation meets growing global food demands. As livestock producers seek to optimize breeding cycles and improve yields, eCG solutions are becoming increasingly sophisticated.
📈 Key Market-Shaping Developments:
- Molecular engineering of recombinant eCG alternatives
- Tightening animal welfare regulations in hormone collection
- Emergence of precision livestock farming technologies
- Growing adoption in developing dairy industries
- Consolidation among Chinese manufacturers
Regional Growth Projections:
- Asia-Pacific: 5.8% CAGR (2023-32) led by China’s pork industry expansion
- Latin America: 4.9% growth through commercial cattle operations
- Europe: Stable 3.7% growth despite regulatory constraints
- North America: Steady 4.3% increase in dairy breeding applications
The profiled companies represent the vanguard of reproductive science, developing solutions that enhance global food security while navigating evolving ethical and regulatory landscapes.
Read Full Report: Equine Chorionic Gonadotropin (eCG) for Injection Market – View in Detailed Research Report